Voisin Consulting Life Sciences glossary icon

Innovative Licensing and Access Pathway (ILAP)

Click a letter to view all its definitions

The MHRA’s Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications, and repurposed medicines. 

Horizon scanning and regulatory science will make sure the pathway is at the forefront of innovative developments and has the framework to develop evidence-based practice as modern technologies and methods emerge. 

The ILAP is open to both commercial and non-commercial developers of medicines (UK based and or global). It comprises of an Innovation Passport designation, a Target Development Profile (TDP) and provides applicants with access to a toolkit to support all stages of the design, development, and approvals process. 

The ILAP provides opportunities for enhanced regulatory and other stakeholder input. 

Other glossary definitions


Comparative Effectiveness Analysis (CEA)

A systematic evaluation of the evidence on the outcomes of different drugs or other options…

View definition

Clinical Study Report (CSR)

Upon completion of a clinical trial, the sponsor is required to prepare a detailed report…

View definition